Effect of Low-dose Esketamine on Maternal Depression at 2 Years After Childbirth
Status:
Active, not recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
Postpartum depression refers to the depression after childbirth, which is a common mental
disorder in women. The pathogenesis of postpartum depression is not fully understood, and may
be related to a variety of factors. Prenatal depression is an important risk factor for
postpartum depression. Our recent multicenter randomized controlled trial, "Effect of
Low-dose esketamine on the incidence of postpartum depression in women with prenatal
depression", explored the effect of immediate postpartum intravenous infusion of low-dose
esketamine on the incidence of postpartum depression in women with prenatal depression. The
preliminary results showed that it reduced the incidence of postpartum depression at 42 days.
Since there were no studies on the effect of intravenous esketamine infusion after delivery
on long-term postpartum depression, this study is a long-term follow-up of the previous
randomized trial. We aim to explore the effect of low-dose intravenous esketamine after
delivery on the incidence of 2-year maternal depression after delivery in women with prenatal
depressive symptoms.